Our commitment to safety communication

Verified safety updates from ongoing ocrelizumab clinical trials and post-marketing experience

As of December 2020, more than 200,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 300,000 patient-years.1

> 6,000 patients in clinical trials and open-label extension

> 195,000 patients with post-marketing experience

Our commitment to safety communication

Verified safety updates from ongoing ocrelizumab clinical trials and post-marketing experience

As of December 2020, more than 200,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 300,000 patient-years.1

> 6,000 patients in clinical trials and open-label extension

> 195,000 patients with post-marketing experience

Updated safety analysis

Learn more

Additional topics of interest

Learn more

Post-marketing commitments

Learn more

Prescribing information

Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.

References

1. Roche data on file: 31 December 2020, post-marketing experience; 27 March 2020, clinical trials data cut-off